Your browser doesn't support javascript.
loading
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Kudling, Tatiana V; Clubb, James H A; Pakola, Santeri; Quixabeira, Dafne C A; Lähdeniemi, Iris A K; Heiniö, Camilla; Arias, Victor; Havunen, Riikka; Cervera-Carrascon, Victor; Santos, Joao M; Sutinen, Eva; Räsänen, Jari; Borenius, Kristian; Mäyränpää, Mikko I; Aaltonen, Eero; Sorsa, Suvi; Hemminki, Otto; Kanerva, Anna; Verschuren, Emmy W; Ilonen, Ilkka; Hemminki, Akseli.
Afiliação
  • Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Pakola S; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Lähdeniemi IAK; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Heiniö C; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Arias V; Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLife, University of Helsinki, Helsinki, Finland.
  • Havunen R; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
  • Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Sutinen E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Räsänen J; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Borenius K; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Mäyränpää MI; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Aaltonen E; Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Sorsa S; TILT Biotherapeutics Ltd, Helsinki, Finland.
  • Hemminki O; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
  • Kanerva A; Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Verschuren EW; Department of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland.
  • Ilonen I; General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Hemminki A; iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Oncoimmunology ; 12(1): 2241710, 2023.
Article em En | MEDLINE | ID: mdl-37546696
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interleucina-2 / Fator de Necrose Tumoral alfa / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interleucina-2 / Fator de Necrose Tumoral alfa / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Finlândia